Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in Recurrent or Metastatic Salivary Gland Cancer
NCT02558387Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Nov 2014
- Primary completion
- Jul 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib in salivary gland cancer (SGC), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
nintedanib
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT02558387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02558387.